Stock Track | NovoCure Plummets 5.18% as Wells Fargo Downgrades Stock and Slashes Price Target

Stock Track

Jul 25, 2025

NovoCure Ltd. (NVCR) shares plunged 5.18% in pre-market trading on Friday following a significant downgrade and price target cut by Wells Fargo. The medical device company, known for its innovative cancer treatments, faced a harsh reassessment from one of Wall Street's major financial institutions.

Wells Fargo downgraded NovoCure from Overweight to Equal Weight, signaling a less optimistic outlook on the stock's potential for outperformance. Simultaneously, the bank drastically reduced its price target for NovoCure from $40 to $14.5, representing a 63.75% cut. This substantial reduction in the price target suggests a significantly lowered expectation for the company's future performance and valuation.

The timing of this downgrade coincides with NovoCure's recent release of its Q2 2025 financial results. While the specific details of the earnings report were not provided, the combination of the earnings release and the subsequent downgrade implies that the company's financial performance or outlook may have disappointed analysts. Investors reacted swiftly to these developments, leading to the sharp decline in NovoCure's stock price during pre-market trading.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/1187214281"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1187214281\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1187214281?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-07-25 21:54","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1187214281","market":"us","top_or_hot":-1,"title":"Stock Track | NovoCure Plummets 5.18% as Wells Fargo Downgrades Stock and Slashes Price Target","media":"Stock Track","content":"<p>NovoCure Ltd. (NVCR) shares plunged 5.18% in pre-market trading on Friday following a significant downgrade and price target cut by Wells Fargo. The medical device company, known for its innovative cancer treatments, faced a harsh reassessment from one of Wall Street's major financial institutions.</p>\n\n<p>Wells Fargo downgraded NovoCure from Overweight to Equal Weight, signaling a less optimistic outlook on the stock's potential for outperformance. Simultaneously, the bank drastically reduced its price target for NovoCure from $40 to $14.5, representing a 63.75% cut. This substantial reduction in the price target suggests a significantly lowered expectation for the company's future performance and valuation.</p>\n\n<p>The timing of this downgrade coincides with NovoCure's recent release of its Q2 2025 financial results. While the specific details of the earnings report were not provided, the combination of the earnings release and the subsequent downgrade implies that the company's financial performance or outlook may have disappointed analysts. Investors reacted swiftly to these developments, leading to the sharp decline in NovoCure's stock price during pre-market trading.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | NovoCure Plummets 5.18% as Wells Fargo Downgrades Stock and Slashes Price Target</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | NovoCure Plummets 5.18% as Wells Fargo Downgrades Stock and Slashes Price Target\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2025-07-25 21:54</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>NovoCure Ltd. (NVCR) shares plunged 5.18% in pre-market trading on Friday following a significant downgrade and price target cut by Wells Fargo. The medical device company, known for its innovative cancer treatments, faced a harsh reassessment from one of Wall Street's major financial institutions.</p>\n\n<p>Wells Fargo downgraded NovoCure from Overweight to Equal Weight, signaling a less optimistic outlook on the stock's potential for outperformance. Simultaneously, the bank drastically reduced its price target for NovoCure from $40 to $14.5, representing a 63.75% cut. This substantial reduction in the price target suggests a significantly lowered expectation for the company's future performance and valuation.</p>\n\n<p>The timing of this downgrade coincides with NovoCure's recent release of its Q2 2025 financial results. While the specific details of the earnings report were not provided, the combination of the earnings release and the subsequent downgrade implies that the company's financial performance or outlook may have disappointed analysts. Investors reacted swiftly to these developments, leading to the sharp decline in NovoCure's stock price during pre-market trading.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"NVCR","symbol_name":"NovoCure Limited","start_time":0,"source_url":"","article_id":"1187214281","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1187214281","pubTimestamp":1753451661,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"NovoCure Ltd. (NVCR) shares plunged 5.18% in pre-market trading on Friday following a significant downgrade and price target cut by Wells Fargo. The medical device company, known for its innovative...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"NVCR":"NovoCure Limited"},"translate_title":"个股追踪|NovoCure暴跌5.18%富国银行下调股票评级并大幅下调目标价","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NVCR":1},"content_text":"NovoCure Ltd. (NVCR) shares plunged 5.18% in pre-market trading on Friday following a significant downgrade and price target cut by Wells Fargo. The medical device company, known for its innovative cancer treatments, faced a harsh reassessment from one of Wall Street's major financial institutions.\nWells Fargo downgraded NovoCure from Overweight to Equal Weight, signaling a less optimistic outlook on the stock's potential for outperformance. Simultaneously, the bank drastically reduced its price target for NovoCure from $40 to $14.5, representing a 63.75% cut. This substantial reduction in the price target suggests a significantly lowered expectation for the company's future performance and valuation.\nThe timing of this downgrade coincides with NovoCure's recent release of its Q2 2025 financial results. While the specific details of the earnings report were not provided, the combination of the earnings release and the subsequent downgrade implies that the company's financial performance or outlook may have disappointed analysts. Investors reacted swiftly to these developments, leading to the sharp decline in NovoCure's stock price during pre-market trading.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}